Literature DB >> 24018412

Diabetes: Legacy effects of RAS blockade in diabetes mellitus.

Christos Chatzikyrkou1, Jan Menne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24018412     DOI： 10.1038/nrneph.2013.173

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

Authors:  Ian H de Boer; Wanjie Sun; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Bernard Zinman
Journal:  N Engl J Med       Date:  2011-11-12       Impact factor: 91.245

2.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

3.  Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.

Authors:  Piero Ruggenenti; Esteban Porrini; Nicola Motterlini; Annalisa Perna; Aneliya Parvanova Ilieva; Ilian Petrov Iliev; Alessandro Roberto Dodesini; Roberto Trevisan; Antonio Bossi; Giuseppe Sampietro; Enrica Capitoni; Flavio Gaspari; Nadia Rubis; Bogdan Ene-Iordache; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2012-08-30       Impact factor: 10.121

4.  Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.

Authors:  Jackie Bosch; Eva Lonn; Janice Pogue; J Malcolm O Arnold; Gilles R Dagenais; Salim Yusuf
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

5.  Long-term follow-up after tight control of blood pressure in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; H Andrew W Neil; David R Matthews
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

6.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

7.  Renal and retinal effects of enalapril and losartan in type 1 diabetes.

Authors:  Michael Mauer; Bernard Zinman; Robert Gardiner; Samy Suissa; Alan Sinaiko; Trudy Strand; Keith Drummond; Sandra Donnelly; Paul Goodyer; Marie Claire Gubler; Ronald Klein
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

8.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

9.  Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus.

Authors:  David Z I Cherney; Bernard Zinman; Christopher R J Kennedy; Rahim Moineddin; Vesta Lai; Stuart Yang; Judith A Miller; Stephenie D Prokopec; Paul C Boutros; James W Scholey; Heather N Reich
Journal:  Kidney Int       Date:  2013-06-12       Impact factor: 10.612

10.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245
  10 in total
  1 in total

1.  The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.

Authors:  Jan Menne; Eberhard Ritz; Luis M Ruilope; Christos Chatzikyrkou; Giancarlo Viberti; Hermann Haller
Journal:  J Am Heart Assoc       Date:  2014       Impact factor: 5.501
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.